Adenocarcinoma is a type of cancer that originates in glandular tissue, which lines organs and forms the secretory portions of glands. It commonly affects organs like the lungs, colon, prostate, pancreas, and breast. Research in adenocarcinoma focuses on understanding genetic mutations and molecular pathways that drive its development and progression. Advances in genomic sequencing have identified key mutations, such as those in the KRAS, EGFR, and BRAF genes, which are pivotal in personalized medicine approaches. Current studies also explore the tumor microenvironment and its role in cancer growth and metastasis. Novel treatments, including targeted therapies and immunotherapies, are being developed and tested in clinical trials, aiming to improve survival rates and quality of life for patients with adenocarcinoma.
Title :
Patricia Tai, Saskatchewan Cancer Agency, Canada
Title :
Atif A Ahmed, Seattle Children’s Hospital, United States
Title :
Marika Crohns, Sanofi, Germany
Title : A novel mRNA genomic technology for precision medicine, early cancer diagnosis, prognosis, treatment follow-up and cancer gene therapy
Rajvir Dahiya, University of California San Francisco, United States
Title : The future of pharmacogenetic polymorphism, pharmacogenomics and pharmamicrobiome in cancer treatment
Bene Ekine-Afolabi, University of East London, United Kingdom
Title : Biosensor-based detection of cancer biomarkers
Michael Thompson, University of Toronto, Canada